Vergoeding 2019-2023 voor ATC-subgroep C10AX : Overige antilipaemica
- Raming voor de totale Zvw-populatie
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| C10AX06 Omega-3-vetzuurpreparaat (Vazkepa ®) | . | . | . | . | 23.103 |
| C10AX09 Ezetimib (Ezetrol ®) | 7.315.400 | 6.281.900 | 4.933.200 | 5.317.600 | 5.529.400 |
| C10AX12 Lomitapide (Lojuxta ®) | 1.530.800 | 1.563.700 | 2.142.400 | 1.922.200 | 1.599.500 |
| C10AX13 Evolocumab (Repatha ®) | 39.992.200 | 48.273.000 | 55.537.900 | 66.601.700 | 76.832.000 |
| C10AX14 Alirocumab (Praluent ®) | 30.221.700 | 41.041.300 | 47.665.500 | 58.487.900 | 65.779.200 |
| C10AX15 Bempedoinezuur (Nilemdo ®) | . | . | . | . | 185.120 |
| C10AX16 Inclisiran (Leqvio ®) | . | . | . | 2.819.700 | 6.144.900 |
| Totaal | 79.060.100 | 97.159.900 | 110.279.000 | 135.149.100 | 156.093.223 |